Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

The potential is just terrific imo. The public health research institute added to the list. The catalysts just keep on building. And we still have the Alfa licensing as well. I'm wondering who is doing the consulting, I doubt Leo is doing it alone. Maybe Locust Walk has a hand in it? I dunno.

But yeah, I've been adding to my IRA and my taxable account. There's been a lockdown on many of the covid bio chasers, we'll see if they have the goods but imo, the way IPIX is progressing we could be well on our way to solid data that proves its worth against the virus. A matter of weeks for the lung data and still waiting to hear something from the university.

Feb 24 Asia
http://www.ipharminc.com/press-release/2020/2/24/innovation-pharmaceuticals-submits-material-transfer-agreement-to-study-lead-defensin-mimetic-brilacidin-for-coronavirus-covid-19


March 5th P2 trial for UC reviewing CRO's
http://www.ipharminc.com/press-release/2020/3/5/innovation-pharmaceuticals-plans-for-phase-2-trial-of-new-treatment-for-ulcerative-colitis

March 6 A major U.S. university
http://www.ipharminc.com/press-release/2020/3/6/innovation-pharmaceuticals-signs-second-mta-to-explore-brilacidin-as-coronavirus-covid-19-treatment

March 9 Regional Biocontainment Labs (RBLs) in the United States
http://www.ipharminc.com/press-release/2020/3/9/innovation-pharmaceuticals-brilacidin-received-by-us-regional-biocontainment-laboratory-testing-against-coronavirus-covid-19

May 5th A public health research institute
http://www.ipharminc.com/press-release/2020/5/5/inhibitory-effect-of-innovation-pharmaceuticals-brilacidin-on-sars-cov-2-covid-19-in-primary-human-immune-cells-to-be-studied-at-leading-public-health-research-institute

A lot going on that's for sure. And MUCH of it on their dime, not ours!

Message in reply to:

Every time I add I can't help but consider and add some for my ever present partner, 80% for me 20% for partner. US Government, this is one of the times I have ne regrets, they are truly investing on our behalf.